HippoScreen Neurotech focuses on brainwave signal processing and artificial intelligence technology to develop innovative medical services for brainwave-assisted diagnosis and assessment. Their vision is to promote early detection and treatment to enhance the mental and brain health. Their brainwave device has received FDA 510(k) clearance in the United States and a medical device license from Taiwan FDA, making them the first domestic manufacturer of medical-grade brainwave devices. They have also obtained ISO 13485 certification and a BSI certificate.
Their first product, the “Stress EEG Assessment (SEA) System,” was developed for depression detection by collecting clinical data from three major hospitals and received a software medical device license from Taiwan FDA in October 2023. Initially, they aim to establish the company’s brand professionalism with medical products and then expand to explore applications such as corporate EAP and mental health screening.
They are also developing a second product, the “Brain Degeneration Risk Assessment System,” for early risk detection of MCI (Mild Cognitive Impairment), which is currently undergoing clinical trials for registration. They hope that these two products will enhance the quality of life in an aging society by entering the healthcare system and cultivating the health prevention market, providing objective and quantitative assessment indices. These products will serve as important AI assistants for professional medical personnel and for general mental and brain health screening.